Regulatory Shift and Legal Action Boost Novo Nordisk Shares
Published on 02/09/2026 at 15:41 | Redaktion boerse-global.de
Shares of the Danish pharmaceutical giant Novo Nordisk surged by more than 8% on Monday. This significant gain followed a dual development that alleviated competitive pressures in the lucrative U.S. weight-loss drug market.
The positive momentum began when telemedicine provider Hims & Hers announced over the weekend that it would halt sales of its low-cost semaglutide product. Semaglutide is the active ingredient in Novo Nordisk’s blockbuster drug, Wegovy. The competitor’s offering, priced at a fraction of Wegovy’s cost, had been viewed by the market as a substantial threat to Novo’s pricing power in the multi-billion dollar sector. Its withdrawal was announced just days after its launch.
FDA Read more...
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
